Post

New research · Obstetrics & Gynecology
Medical sciences (Basel, Switzerland) · 1w
Cohort studyMedical sciences (Basel, Switzerland) · 2026

Improved Prognostic Staging in Endometrial Cancer: Clinical Impact of Aggressive Subtypes in a Multicenter Cohort.

Tatiana Cuesta-Guardiola, Alicia Quirós, Pluvio Jesús Coronado Martín, Augusto Pereira Sánchez
Read paper
Obstetrics & GynecologyCohort study

Aggressive endometrial cancer subtypes were linked to markedly shorter overall survival

Improved Prognostic Staging in Endometrial Cancer: Clinical Impact of Aggressive Subtypes in a Multicenter Cohort.

Tatiana Cuesta-Guardiola … Augusto Pereira Sánchez
Medical sciences (Basel, Switzerland) · 2026
Purpose

Assessment of the impact on survival of endometrial carcinoma according to the 2009 FIGO (International Federation of Gynecology and Obstetrics) classification and the new FIGO 2023 classification highlighting the worse prognosis of the aggressive subtypes.

Methods

This multicenter retrospective study included 1181 patients with endometrial cancer.

n = 1181 patients
Results

people with aggressive tumor types typically lived a much shorter time overall

Aggressive
35.7months
Non-aggressive
60months
More results

A novel classification based on FIGO 2023 was developed, integrating histological aggressiveness into a different stage and combining early non-aggressive stages in only one stage.

While FIGO 2009 and 2023 classifications showed prognostic value, the new model improved risk stratification, clearly distinguishing high-risk groups.

More results

Multivariate analysis identified aggressive subtype, stage, age, diabetes, myometrial invasion and lymphovascular invasion as independent predictors.

“
Conclusion · 1 of 2

Aggressive histological subtype in endometrial cancer should carry greater prognostic weight in terms of survival and clinical management.

Conclusion · 2 of 2

Our findings support a potential shift in the current paradigm for these relatively rare but high-risk cases.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Randomized Trial
hazard ratio 0.43
cancer was much less likely to grow or come back during follow-up
Randomized Trial
2.52%
similarly low rate of cancer returning in the pelvis after simpler, less extensive surgery
Study
120
essential learning goals international experts agreed every global surgery training program should cover
Cohort Study
HR 0.85
The hazard of death was similar with adjuvant chemoradiotherapy versus radiotherapy alone.
Randomized Trial
HR 0·42
for p53-abnormal tumors, combined treatment nearly halved the risk of cancer returning
Randomized Trial
-2.3 percentage points
the chance of staying cancer-free for 3 years was higher with biopsy only
Study
96.2% (90% CI, 85.9%-97.9%)
high percentage of patients whose hormone levels returned to normal, allowing treatment to stop
Cohort Study
33.3%
Among pregnant women with anemia, a higher percentage had babies born early